US equities |
SPCX $166.96 ▲+5.03% NVDA $237.17 ▲+1.38% MU $1,065.64 ▼-0.86% TSLA $377.36 ▲+1.83% MSFT $525.45 ▲+1.53% INTC $116.53 ▼-2.35% SNDK $1,714.51 ▼-0.32% META $745.67 ▲+2.42%
FinancialContent

Natera, Inc. - Common Stock (NQ:NTRA)

416.48 +6.13 (+1.49%)
Delayed Quote Updated: 11:15 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
23 24 Next >
News headline image
Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
From Natera, Inc.
Via Business Wire
News headline image
Peering Into Natera's Recent Short Interest ↗
 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring Natera Through Analyst Insights ↗
 
Via Benzinga
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
The recent stock market dip provided some discounts. 
Via The Motley Fool
News headline image
Shopify, Palantir And Uber Are Among Top 10 Large Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio? ↗
Top 10 best performing large-cap stocks last week: Shopify, Palantir, Axon, Fortinet, Trade Desk, Natera, SharkNinja, Zillow, Aspen Tech, Uber. 
Via Benzinga
News headline image
Forecasting The Future: 6 Analyst Projections For Natera ↗
 
Via Benzinga
News headline image
$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
NTRA Stock Earnings: Natera Beats EPS, Beats Revenue for Q2 2024 ↗
NTRA stock results show that Natera beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Natera Reports Second Quarter 2024 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Natera, Inc.
Via Business Wire
News headline image
(NTRA) - Analyzing Natera's Short Interest ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Natera Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,300 Today ↗
 
Via Benzinga
News headline image
$100 Invested In Natera 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Natera to Report its Second Quarter 2024 Results on August 8, 2024
From Natera, Inc.
Via Business Wire
News headline image
New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma
From Natera, Inc.
Via Business Wire
News headline image
The 3 Best Gene Editing Stocks to Buy in July 2024 ↗
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks. 
Via InvestorPlace
News headline image
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,400 Today ↗
 
Via Benzinga
News headline image
Breaking Down Natera: 10 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
(NTRA) - Analyzing Natera's Short Interest ↗
 
Via Benzinga
News headline image
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
From Natera, Inc.
Via Business Wire
News headline image
Trading SMID Biotech Stocks In A Volatile Market ↗
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
News headline image
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
From Natera, Inc.
Via Business Wire
News headline image
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including 
Via MarketBeat
News headline image
Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients
From Natera, Inc.
Via Business Wire
News headline image
Amazon, Natera And A Financial Stock: CNBC's 'Final Trades' ↗
The recommendation comes after a former Amazon employee accused the Seattle-based company of selling technology to Russia. 
Via Benzinga
News headline image
Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Natera, Inc.
Via Business Wire
News headline image
Cathie Wood-Led Ark Invest Sells Nearly $28M Worth Of Robinhood Shares Amid Crypto API Launch And Lackluster Bitcoin Price Action ↗
On Thursday, Cathie Wood-led Ark Invest made notable adjustments to its portfolio, including a significant sell-off of Robinhood Markets Inc (NASDAQ:HOOD) shares. 
Via Benzinga
News headline image
Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024
From Natera, Inc.
Via Business Wire
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
23 24 Next >